Stocks · Health care · Biological Products, (No Diagnostic Substances)

Eloxx Pharmaceuticals, Inc.

ELOX Clue Score20
United States Fiscal year ends December CIK 0001035354
$13.74 -9.49% Close, 9 Oct 2026
Price $13.74 +15.46% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 9 Jun 2026. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2017Operating income−4.6Net income−5.8Fiscal year 2017Operating income−20.4Net income−21.2Fiscal year 2018Operating income−47.6Net income−47.2Fiscal year 2019Operating income−50.6Net income−50.9Fiscal year 2020Operating income−33.5Net income−34.6Fiscal year 2021Operating income−66.0Net income−66.7EPS, diluted−38.15Fiscal year 2022Operating income−34.4Net income−36.1EPS, diluted−16.65Fiscal year 2023Revenue0.0Operating income−17.3Net income−17.1EPS, diluted−6.63Fiscal year 2024Revenue6.4Operating income−2.5Net income−3.1EPS, diluted−0.84Fiscal year 2025Revenue0.0 −100.0%Operating income−6.4Net income−6.0EPS, diluted−0.49
FY2017FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue n/a n/a n/a n/a n/a n/a n/a 0.0 6.4 0.0
Growth −100.0%
Operating income −4.6 −20.4 −47.6 −50.6 −33.5 −66.0 −34.4 −17.3 −2.5 −6.4
Net income −5.8 −21.2 −47.2 −50.9 −34.6 −66.7 −36.1 −17.1 −3.1 −6.0
Growth
EPS, diluted n/a n/a n/a n/a n/a −38.15 −16.65 −6.63 −0.84 −0.49

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2017Fiscal year 2017Fiscal year 2018Fiscal year 2019Fiscal year 2020Fiscal year 2021Fiscal year 2022Fiscal year 2023Fiscal year 2024Operating margin−38.8%Net margin−49.4%Fiscal year 2025
FY2017FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin n/a n/a n/a n/a n/a n/a n/a n/a −38.8% n/a
Net margin n/a n/a n/a n/a n/a n/a n/a n/a −49.4% n/a

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2017Operating cash flow−1.9Capital expenditure−0.0Free cash flow−1.9Fiscal year 2017Operating cash flow−15.9Capital expenditure−0.2Free cash flow−16.2Dividends paid0.0Fiscal year 2018Operating cash flow−31.4Capital expenditure−0.2Free cash flow−31.6Dividends paid0.0Fiscal year 2019Operating cash flow−39.4Capital expenditure−0.0Free cash flow−39.4Dividends paid0.0Fiscal year 2020Operating cash flow−28.2Fiscal year 2021Operating cash flow−35.0Capital expenditure−0.1Free cash flow−35.1Fiscal year 2022Operating cash flow−31.8Capital expenditure−0.1Free cash flow−31.9Fiscal year 2023Operating cash flow−14.3Fiscal year 2024Operating cash flow−4.7Fiscal year 2025Operating cash flow−6.3
FY2017FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −1.9 −15.9 −31.4 −39.4 −28.2 −35.0 −31.8 −14.3 −4.7 −6.3
Capital expenditure −0.0 −0.2 −0.2 −0.0 n/a −0.1 −0.1 n/a n/a n/a
Free cash flow −1.9 −16.2 −31.6 −39.4 n/a −35.1 −31.9 n/a n/a n/a
Growth
Dividends paid n/a 0.0 0.0 0.0 n/a n/a n/a n/a n/a n/a

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2017Cash0.0Shareholders’ equity0.9Fiscal year 2017Cash24.0Shareholders’ equity21.4Fiscal year 2018Cash48.6Shareholders’ equity42.9Fiscal year 2019Cash22.5Total debt14.8Net cash (debt)7.7Shareholders’ equity36.2Debt to equity0.41Fiscal year 2020Cash24.7Total debt11.6Net cash (debt)13.1Shareholders’ equity10.2Debt to equity1.14Fiscal year 2021Cash42.3Total debt12.0Net cash (debt)30.3Shareholders’ equity22.4Debt to equity0.54Fiscal year 2022Cash19.2Total debt12.5Net cash (debt)6.7Shareholders’ equity−10.7Fiscal year 2023Cash1.1Total debt3.8Net cash (debt)−2.7Shareholders’ equity−22.6Fiscal year 2024Cash0.1Total debt6.5Net cash (debt)−6.4Shareholders’ equity−24.3Fiscal year 2025Cash4.8Total debt1.0Net cash (debt)3.8Shareholders’ equity−11.9
FY2017FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 0.0 24.0 48.6 22.5 24.7 42.3 19.2 1.1 0.1 4.8
Total debt n/a n/a n/a 14.8 11.6 12.0 12.5 3.8 6.5 1.0
Net cash (debt) n/a n/a n/a 7.7 13.1 30.3 6.7 −2.7 −6.4 3.8
Shareholders’ equity 0.9 21.4 42.9 36.2 10.2 22.4 −10.7 −22.6 −24.3 −11.9
Debt to equity n/a n/a n/a 0.41 1.14 0.54 n/a n/a n/a n/a

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Balance sheet

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2016 31 Dec 2016 FY2017 30 Jun 2017 FY2017 31 Dec 2017 FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025† 31 Dec 2025
Assets
2.2 0.0 24.0 48.6 22.5 24.7 42.3 19.2 1.1 0.1 4.8
0.0 0.1 0.3 0.2 0.2 0.1 0.2 0.2 0.0 0.0 0.0
3.1 5.8 24.8 50.7 58.9 26.5 45.1 21.1 1.7 3.0 5.3
Growth +86.9% +324.0% +104.6% +16.2% −55.1% +70.5% −53.2% −91.9% +73.8% +77.1%
Liabilities
n/a n/a n/a n/a 4.3 5.2 0.0 4.0 2.2 6.5 1.0
n/a n/a n/a n/a 10.5 6.4 12.0 8.6 1.6 0.0 0.0
calc n/a n/a n/a n/a 14.8 11.6 12.0 12.5 3.8 6.5 1.0
3.0 5.0 n/a 7.8 22.7 16.2 22.8 31.8 24.3 27.3 17.2
Equity
−17.7 −121.8 −39.0 −86.1 −137.0 −171.6 −238.3 −274.4 −291.4 −294.6 −300.6
0.6 0.9 21.4 42.9 36.2 10.2 22.4 −10.7 −22.6 −24.3 −11.9
Growth +42.8% +2,351.9% +100.9% −15.6% −71.8% +118.8% −147.6%
Per share and net cash
calc n/a n/a n/a n/a 7.7 13.1 30.3 6.7 −2.7 −6.4 3.8
4.2 29.2 27.5 35.9 40.0 40.2 2.2 2.2 3.1 3.5 4.8
calc 0.15 0.03 0.78 1.20 0.90 0.25 10.33 −4.92 −7.19 −6.89 −2.49

† The diluted share count jumps at 2025, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Lines marked calc are worked out here from filed figures; point at one for how.